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Inhaled corticosteroid therapy (ICS) for asthma is currently modified according to symptoms 
and lung function. Fractional exhaled nitric oxide (FENO) has been demonstrated to be a 
non-invasive marker of eosinophilic inflammation. Studies of FENO-driven asthma 
management show variable success.  
Objectives 
This study aimed to evaluate whether monitoring FENO can improve outpatient management 
of children with moderate to severe asthma using a pragmatic design.   
Methods 
Children aged 6-17 years with moderate to severe asthma were recruited. Their asthma was 
stabilised before randomisation to FENO-driven therapy or to a standard management group 
where therapy was driven by conventional markers of asthma control. ICS or long-acting 
bronchodilator therapies were altered according to FENO levels in combination with reported 
symptoms in the FENO group. Participants were assessed 2-monthly for 12 months. ICS dose 
and exacerbation frequency change were compared between groups in an intention to treat 
analysis. 
Results 
Ninety children were randomised. No difference was found between the two groups in either 
change in corticosteroid dose or exacerbation frequency. Results were similar in a planned 
secondary analysis of atopic asthmatics. 
Conclusion 
FENO-guided ICS titration does not appear to reduce corticosteroid usage or exacerbation 
frequency in paediatric outpatients with moderate to severe asthma. This may reflect 
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limitations in FENO-driven management algorithms, as there are now concerns that FENO 
levels relate to atopy as much as they relate to asthma control.  
Trial registration: Controlled-Trials ISRCTN50872816. 
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The trial was approved by Southampton and South West Hampshire Research Ethics 
Committee (06/Q1702/9) and registered with Controlled-Trials.Com (ISRCTN50872816). 
Informed consent was obtained from each child’s parents. 
INTRODUCTION 
 
Asthma is a disease of airway inflammation [1]. Sputum eosinophil count-guided 
management has been shown to reduce exacerbation frequency in adult patients without 
increasing inhaled corticosteroid dose [2]. However, sputum induction can be difficult in 
young children [3]. Inhaled corticosteroid therapy (ICS) in asthmatic children is currently 
modified according to symptoms and lung function, both of which poorly reflect airway 
inflammation [4] and poorly predict exacerbations [5]. A suitable clinical measure of airway 
inflammation might enable optimisation of individual patients’ ICS dose.  
 
Fractional exhaled nitric oxide (FENO) has been proposed as a non-invasive measure of 
eosinophilic inflammation which can be measured in children [6] and may be a marker of 
asthma control. [7-10] Asthmatic subjects have higher mean FENO concentrations than non-
asthmatic controls [11] and FENO has been shown to increase with worsening asthma control 
[6] and with allergen exposure in children with grass pollen-induced asthma [9] Inhaled 
corticosteroids have been shown to reduce FENO in children with asthma [12]. Together 
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these observations suggest that FENO varies with the severity of airway inflammation and 
may therefore provide a useful marker of disease severity.  
 
Proof of concept studies suggest that adjusting ICS dose according to monitored airway 
inflammation might improve clinical outcomes in asthma. Individual studies have suggested 
FENO monitoring results in fewer exacerbations [2], lower corticosteroid requirements [13], 
reduced airway responsiveness [14] and improved lung function [15]. However, a recent 
meta-analysis concluded that, although interventions based upon FENO reduce corticosteroid 
use in adults, FENO-monitoring drives up corticosteroid doses in children [16]. Exacerbation 
frequency was not significantly affected in either children or adults [16].  
 
Previous studies have shown FENO to add little to asthma management [13-15;17-18]; this 
might reflect problems with patient selection, dose-adjustment protocol, or the frequency of 
FENO monitoring or corticosteroid dose adjustment. Few previous studies focused upon 
moderate-severe asthma. Studies of mild-moderate asthma may have been underpowered 
with respect to exacerbations. This prospective, randomised, double-blind study was designed 
to be pragmatic, reflecting actual clinical management in paediatric outpatients, and aimed to 





Participants were recruited from outpatient clinics at Southampton University Hospital, St 
Mary’s Hospital, Portsmouth, St Mary’s Hospital, Isle of Wight and the Royal Hampshire 
County Hospital, Winchester. Inclusion criteria were age 6-17 years, clinical diagnosis of 
asthma and treatment with 400 mcg/day beclomethasone/budesonide or 200 mcg/day 
fluticasone. Asthma diagnosis was based upon a history of typical symptoms,  15% increase 
in forced expiratory volume in 1 second (FEV1) with bronchodilator or diurnal peak 
expiratory flow (PEF) variability  15% [19]. Exclusion criteria were inability to perform 
spirometry or FENO measurement, cigarette smoking, poor treatment adherence, life-
threatening exacerbation or need for maintenance oral prednisolone.  
 
Protocol 
Participants completed a PEF diary, a paediatric asthma quality of life assessment (PADQLQ) 
[20], and underwent aeroallergen skin prick testing (house dust mite, grass pollens, tree 
pollens, cat and dog; ALK-Abelló, Hørsholm, Denmark). Participants with a clinical history 
of IgE-mediated food allergy, rhinitis or eczema, or one or more skin prick tests  3mm 
diameter were considered atopic. Participants’ asthma was stabilised if necessary over 4-16 
weeks prior to randomisation. Computer-generated random numbers were used to assign 
participants at enrolment to either FENO-based or standard management. Participants were 
block randomised according to recruitment centre and randomisation was stratified by 
inhaled corticosteroid dose (400-800 mcg/day or > 800 mcg/day beclomethasone equivalent). 
Group allocation was recorded by a research nurse and communicated to an independent 
clinician responsible for therapy decisions. All participants were assessed identically at each 
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subsequent visit so that participants and the medical staff assessing asthma control were 
unaware of group allocation. Participants were assessed 2-monthly for 12 months. 
 
At each visit, a single measure of FENO (blinded to the patient, family and assessing 
clinician) was taken by a research nurse according to ATS/ERS guidelines, using a portable 
monitor (NIOX MINO; Aerocrine, Solna, Sweden) [6, 21]. After FENO measurement, FEV1 
was measured according to ATS/ERS guidelines [22] using a portable spirometer (KoKo 
version 4; PDS Instrumentation; Louisville, USA). Finally, an assessing clinician (blinded to 
allocation group and FENO) assessed treatment adherence by direct questioning, recorded 
exacerbations and administered a questionnaire reviewing symptoms and reliever use over 
the preceding two months [modified from 23].  
 
Exacerbations were defined as  48 hours of increased asthma symptoms or therapy, or 
decreased PEF (≥ 25%) and classified as mild (requiring increased bronchodilator therapy 
only); moderate (requiring systemic corticosteroids); or severe (requiring ≥ 8 hours admission) 
[modified from 13, 24]. The blinded clinician categorised participants’ asthma as well 
controlled (symptoms and reliever inhaler < 1 per week and FEV1  90% predicted); 
controlled (symptoms or reliever inhaler use 1-2 days per week, or FEV1  80% predicted), 
or poorly controlled (symptoms or reliever inhaler use > 2 days per week, or FEV1 < 80% 
predicted) [modified from 13].  
 
Therapy decisions were taken by a clinician independent of participant assessment following 
a simple algorithm reflecting symptom control for standard management subjects, and FENO 
measurements in addition to symptom control for the FENO group (Table 1). Under standard 
management, therapy was increased if symptoms were poorly controlled and decreased if 
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symptoms were well controlled for 3 months as per the SIGN/BTS guidelines [25](Table 2). 
In the FENO group levels of FENO guided therapy. ICS was decreased if FENO  15ppb and 
symptoms were controlled or well controlled for 3 months in similar steps as for the standard 
management group. Where asthma was poorly controlled and FENO was < 25ppb in the 
FENO group, long-acting beta-agonist (LABA) therapy was maximised before ICS were 
increase. ICS was increased if FENO  25ppb or FENO doubled from baseline. If FENO 
remained raised after increasing by two SIGN/BTS steps, ICS was not further increased 
unless participants were poorly controlled.  
 
Statistical analysis  
Change in ICS dose and exacerbation frequency over 12-month’s follow-up was compared 
between FENO and standard management according to intention to treat. Corticosteroid 
doses were calculated as beclomethasone equivalents (mcg). For subjects with incomplete 
follow-up, the number of exacerbations was divided by the number of months’ participation 
then multiplied by 12 to provide 12 month’s data. Two sample t-tests were used for normally 
distributed data, otherwise two sample Mann-Whitney rank-sum tests were undertaken. A 5% 
significance level was used throughout. Planned secondary analyses were performed: (1) per 
protocol analysis restricted to subjects with complete follow-up and (2) analysis considering 
restricted to participants with atopic asthma. Stata® 11 (Stata Corp., College Station, TX) was 
used for all analyses.  
 
We calculated that data from 90 subjects would provide power to detect the difference 
between a 200 and 100 mcg reduction (SD 150 mcg) in inhaled corticosteroid dose in the two 
groups assuming 80% power and < 5% significance level. There would also be 80% power to 
detect a 20% reduction in exacerbation frequency in the FENO group assuming 2 
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Of the 96 children screened, 90 met the inclusion criteria (Figure 1) and were randomised; 44 
to FENO-based (49%) and 46 to standard management (51%). The two groups were well 
matched at baseline for demographic and clinical features (Table 3). Thirteen (14%) 
participants had incomplete follow-up; ten from the FENO group and three under standard 
management. Eleven participants withdrew at their request, one was withdrawn due to non-
adherence, and one following a life-threatening exacerbation (Figure 1). The groups remained 
well matched when subjects with incomplete follow-up were excluded (data not shown). 
 
In total 584 visits were conducted, symptoms were assessed as controlled on 348 occasions 
(59.6%), well controlled on 115 (19.7%) and poorly controlled on 121 (20.7%). Therapy was 
unchanged on 365 visits (62.5%), increased on 129 (22.1%) and decreased on 90 (15.4%). 
When therapy was increased in the FENO group this reflected FENO alone on 44 occasions 
(50.0%), symptoms alone on 13 occasions (14.8%) and on 31 occasions (35.2%) both 
elevated FENO and poor control was recorded. Of the 43 therapy reductions observed in the 
standard management group 25 occurred with FENO > 15 ppb and would not have occurred 
had the participant been allocated to the FENO group. 
 
Inhaled corticosteroid dose 
As ICS data were highly skewed, median values are reported and non-parametric tests 
applied. ICS dose did not change significantly between initial and final visit in either group 
(FENO p=0.901, Standard p=0.498) (Table 4). There was no significant difference between 
groups in ICS dose at either the initial (visit 0) or final visit (visit 6), nor in change of ICS 
dose during the trial (Figure 2 and Table 4). Thirty-four children in the FENO group and 43 
under standard management completed 12 months’ follow-up. When analysis was restricted 
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to participants with complete follow-up, the ICS dose change was not significantly different 
between groups (p=0.670) and there was no significant between group difference in total ICS 
dose received during follow-up (data not shown). Similarly, no between group difference in 
ICS dose change was seen after restricting the analysis to the 68 children who were atopic 
(p=0.129) (data not shown).  
 
Exacerbation frequency 
Thirty seven subjects in the FENO group (84.1%) and 38 in the standard group (82.6%) 
experienced at least one exacerbation during follow-up. Of these, five in the FENO (11.4%) 
and three in the standard group (6.5%) experienced a severe exacerbation. The number of 
subjects experiencing an exacerbation did not differ between groups (p=0.850) (Table 4); 
neither was there a difference between the groups regarding the number of subjects 
experiencing a severe exacerbation (p=0.420). Time to first exacerbation did not differ 
between groups (p=0.391) (Figure 3). There were no significant between group differences 
for either overall exacerbation frequency or for frequency of mild, moderate or severe 
exacerbations.  
 
There was no between group difference in exacerbation frequency when in order to avoid the 
possible complication of seasonality of exacerbations the analysis was restricted to children 
with complete follow-up (data not shown). Moreover there was no between group difference 
when the analysis was restricted to atopic children (data not shown).  
 
FENO and lung function 
FENO measurements were compared between groups. Neither group experienced a 
significant change in FENO during follow-up (mean (95% CI) +3.1 ppb (−5.5 - +11.6 ppb) 
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FENO and +3.3 ppb (−8.5 - +15.1 ppb) standard group). There were no significant between 
group difference in FENO at any study visit (including baseline) (Figure 4), or in change in 
FENO during follow-up. Neither FEV1, FVC nor FEF25-75% change during follow-up differed 
significantly between groups (data not shown).
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DISCUSSION   
Neither inhaled corticosteroid therapy nor exacerbation frequency differed significantly 
between children with moderate-severe asthma randomised to either standard or FENO-based 
management. The two groups did not differ according to either total ICS dose received or 
change in dose over 12 months’ follow-up. Moreover, neither group showed a significant 
reduction in ICS. Exacerbation frequency did not differ significantly between the two groups 
irrespective of whether exacerbations were or were not associated with an URTI. Similar 
results were found in a planned subgroup analysis restricted to atopic participants, although 
power may have been limited by the smaller numbers included in this analysis.  
 
Inhaled corticosteroid dose 
FENO monitoring theoretically offers a means of matching ICS to eosinophilic inflammation. 
Adult studies have shown some reduction in corticosteroid dose with a FENO-based strategy 
[2]. Conversely, significantly increased corticosteroid doses have been found in paediatric 
studies [15;17]. In this study, although neither the total ICS dose nor change in dose over 12 
months’ follow-up differed significantly according to management group, non-significant 
differences were seen supporting higher ICS prescription in the FENO group. Lower doses in 
the standard management group may have occurred in part as a consequence of the protocol 
design; dose reduction in the FENO arm required both low FENO and good symptom control, 
whilst good symptom control alone was sufficient for dose reduction under standard 
management. In contrast, the adult study which detected a reduction in corticosteroid dose in 
the FENO arm followed a protocol whereby the dose increased in the FENO group only if 
FENO rose above threshold, whilst under standard management any of five control-based 





Whilst conventional markers of asthma control poorly predict exacerbations, there is some 
evidence that exacerbations can be predicted using FENO [26]. It has been hypothesised that 
FENO-based interventions might tailor inhaled corticosteroid dose in a manner which 
reduces exacerbations. Decreased exacerbations might justify small increases in ICS dose. 
Whilst paediatric patients assigned to FENO-based management have been shown to be at 
reduced risk of requiring one or more oral steroid course [17], only two adult studies have 
shown a statistically significant reduction in exacerbation frequency [27, 28]. Previous 
paediatric studies have generally recruited relatively mild asthmatics who would be expected 
to experience infrequent exacerbations. This study recruited moderate-severe asthmatics in 
whom a higher frequency of exacerbations could be expected. Follow-up at 2-monthly 
intervals reflected a compromise between providing adequate opportunity for dose 
modification and avoiding non-specific reduction of exacerbation frequency across both 
groups consequent upon regular follow-up. Exacerbation frequency in this study was greater 
than that in many previous studies but, despite this, reduced exacerbation frequency was not 
seen in the FENO group. This may reflect greater control in closely monitored participants; 
the exacerbation frequency was lower in both groups than that reported for the previous year 
and this may have limited the possibility for further improvement by FENO-monitoring.  
 
Strengths and limitations of this study 
This study employed a pragmatic design to reflect clinical management of moderate-severe 
asthma in paediatric outpatients. Almost 100 children were recruited and participants in this 
study had a greater severity of asthma compared to similar trials. Treatment adherence was 
emphasised at each visit. Two cut-offs were used to up- and down-titrate ICS according to 
FENO level, using a similar protocol, the successful adult trial in pregnant women [27], and 
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provision was made within the protocol to prevent dose escalation at high FENO levels. The 
two groups were well matched for clinical and demographic features; although the standard 
management group contained more males and its members had more past hospital admissions, 
neither of these factors was significantly associated with the main outcomes and therefore 
they were unlikely be confounders.  By chance, the median FENO level was lower in those 
randomised to the FENO group but this difference was not statistically significant. As the 
range of participants’ FENO values in each group wide and almost entirely overlapping, this 
is unlikely to have biased the study results.  
 
Given the theoretical advantage of tailored ICS the lack of empirical support for FENO-based 
interventions is unexpected. It may be argued that, as FENO levels were not significantly 
decreased in the FENO group during this study, airway inflammation was not effectively 
suppressed. Constant low FENO, however, is not necessarily the aim of FENO-based 
monitoring; rather variation in FENO might reflect variation in airway inflammation thereby 
improving ICS prescription by providing more sensitive dose titration than that based upon 
conventional markers of asthma control. Further explanations are required for the inability to 
demonstrate a clinically useful effect of FENO monitoring.  
 
Aspects of protocol design might in part be responsible for lack of success in this and 
previous studies [13-15, 16,17]. For example, the long run-in period in this study may have 
optimised management thereby limiting further improvement. FENO-driven therapy may 
have been more effective if the study had been restricted to atopic-asthma [29]. Choice of 
FENO cut-off or the frequency of monitoring and dose adjustment might also affect study 
outcomes. There may be a need for ICS dosages to be increased more dramatically in the face 
of a high FENO level to adequately suppress airway inflammation. Disappointingly, however, 
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studies using intensive telemonitoring [18] or sophisticated multi-level FENO cut-offs [17] to 
address these issues have failed to reveal a benefit associated with FENO monitoring.  
 
It is becoming evident that factors other than protocol design might account for the lack of 
success of this and similar studies. Given that sputum eosinophil-based management has been 
used successfully to reduce exacerbations [2], it is possible that FENO-based strategies are 
unsuccessful because FENO does inaccurately represents eosinophilic inflammation. 
Moreover, we now know that FENO provides little useful information regarding non-
eosinophilic inflammation, for example high levels of neutrophilic inflammation may be 
associated with reduced FENO independent of eosinophil number [30]. We have recently 
shown that FENO has been shown to correlate more closely with atopy than with asthma and 
to vary little with increasing frequency of wheezing attacks in non-atopic asthmatics [29]. It 
appears that high FENO levels in some individuals cannot be reduced by higher 
corticosteroid doses [31], possibly because of retrograde flow in association with severe 
rhinitis. These findings suggest that FENO is influenced by factors other than asthma and that 
in some patients, non-invasive markers of airway inflammation are disconnected from asthma 
symptoms [32]. Together these factors suggest the efficacy of FENO-guided strategies may 
vary according to the population in which they are employed and cast doubt upon the 
appropriateness of pre-defined FENO cut-offs.  
 
Empirical support for FENO-based management has been found in atopic and in obese 
subjects [17]. This study considered the issue of atopy but was not adequately powered to 
support sub-analyses. Theoretically increased effectiveness compared to conventional 
management might be expected in subjects discordant for FENO levels and symptoms. 
Patients who show an increase in FENO following ICS reduction whilst experiencing no 
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immediate deterioration in symptoms might represent a subgroup in which FENO-based 
management is most successful, identifying and randomising such individuals might 
represent an optimal trial paradigm.  
 
The FENO cut-off used to direct treatment decisions is critical and may explain differences 
seen between studies; too low a cut-off predisposes to higher inhaled corticosteroid doses in 
the FENO group whilst too high might fail to reduce exacerbation frequency. FENO 
standardised by an individual’s previous best value has been demonstrated to correlate with 
asthma control [9]. An alternative to pre-defined cut-offs might be to adjust corticosteroid 
dose according to an individual’s personal best FENO level; this has yet to be assessed.  
 
Conclusions 
No difference was found in either the inhaled corticosteroid dose or the exacerbation 
frequency between children with moderate-severe asthma randomised to either standard or 
FENO-based management. Furthermore, no particular benefit was found for atopic children. 
At present there is little evidence to support the use of FENO monitoring in routine outpatient 
management of paediatric asthma.  
 
ABBREVIATIONS 
FENO  Fractional exhaled nitric oxide 
FEV1  Forced expiratory volume in 1 second 
ICS  Inhaled corticosteroid therapy  
IQR  Interquartile range  
LABA  Long-acting beta-agonist 
PAQLQ Paediatric asthma quality of life assessment  
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PEF  Peak expiratory flow 
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Figure 1 Flow of participants through the study, comparison of numbers in the FENO 
and standard management groups 
Incomplete follow up in FENO group: two dropped out after visit 1, two after visit 2, three 
after visit 3 (one with a life threatening exacerbation and one due to non-compliance), one 
after visit 4 and two after visit 5.  In the standard management group, one participant dropped 
out after visits 3, 4 and 5.  
 
 
Figure 2 Inhaled corticosteroid dose at each visit according to randomisation to either 
FENO or standard management group 
Points represent median inhaled corticosteroid dose in beclomethasone equivalents (mcg) at 
each visit for each group while the bars represent the interquartile range.  
 
 
Figure 3 Kaplan-Meier survival estimates comparing time to first exacerbation in days 
for subjects in the Standard and FENO management groups 
Curve represents the proportion of participants in each group who have not experienced an 
exacerbation at each time point.  
 
 
Figure 4 FENO measurements at each visit according to randomisation to either FENO 
or standard management group. 
Points are geometric mean measurements for each group at each visit with bars representing 




Table 1. Algorithm for managing asthma  
FENO group 





Increase inhaled corticosteroids 
or add LTRA if already at 
BTS/SIGN* step 4 
If after increasing by two 
BTS/SIGN* steps FENO 
remains high do not increase 
therapy further 
Increase inhaled corticosteroids or add LTRA if 
already at BTS/SIGN* step 4 
>15 to <25ppb 
Increase LABA therapy; if dose 
maximal, increase 
corticosteroids or add LTRA if 
already at BTS/SIGN* step 4 
Continue current treatment 
15ppb 
Increase LABA; if dose 
maximal, increase 
corticosteroids or add LTRA if 
already at BTS/SIGN* step 4 
If asthma controlled for 3 months, reduce inhaled 
corticosteroids; if dose 400mcg, reduce LABA 
Standard management group 
Poorly controlled asthma Asthma controlled Well controlled asthma 
Increase inhaled corticosteroids or add LABA 
and/or LTRA as directed by stepwise approach to 
therapy BTS/SIGN* 
No change in inhaled 
corticosteroids 
If well controlled for 3 
months, reduce inhaled 
corticosteroids; if dose 
400mcg, reduce LABA 
  
*United Kingdom guidelines on asthma [25]. Levels of asthma therapy are detailed in Table 
2. LABA: long-acting bronchodilator; LTRA: leukotriene receptor antagonist. 
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Table 2 Asthma therapy levels 
Step Option 1 Option2 Option3 
1 No inhaled corticosteroid No inhaled corticosteroid No inhaled corticosteroid 
2 Beclometasone 50mcg twice 
a day via spacer  
Budesonide 50mcg twice a 
day via spacer (or turbohaler) 
Fluticasone 50mcg once a 
day via spacer (or accuhaler) 
3 Beclometasone 100mcg twice 
a day via spacer  
Budesonide 100mcg twice a 
day via spacer (or turbohaler) 
Fluticasone 50mcg twice a 
day via spacer (or accuhaler) 
4 Beclomethasone 200mcg 
twice a day via spacer  
Budesonide 200mcg twice a 
day via spacer (or turbohaler) 
Fluticasone 100mcg twice a 
day via spacer (or accuhaler) 
5 Trial of LABA. If ineffective, 
consider trial of LTRA.  
Trial of LABA. If ineffective, 
consider trial of LTRA. 
Trial of LABA. If ineffective, 
consider trial of LTRA.  
6 Fluticasone 125mcg twice a 
day via spacer 
Fluticasone 125mcg twice a 
day via spacer 
Fluticasone 125mcg twice a 
day via spacer 
7 Fluticasone 250mcg twice a 
day via spacer 
Fluticasone 250mcg twice a 
day via spacer 
Fluticasone 250mcg twice a 
day via spacer 
8 Consider short course of 
prednisolone or other 
therapeutic options. 
Consider short course of 
prednisolone or other 
therapeutic options. 
Consider short course of 
prednisolone or other 
therapeutic options. 
 
Levels of asthma therapy. Modified from British guidelines on the management of asthma 
[25]. LABA: long-acting bronchodilator. LTRA: leukotriene receptor antagonist.  
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Table 3 Comparison of the baseline demographic and clinical features of children in the 
FENO and standard management groups.  






Demographics    
Age years mean (SD) 10.51 (2.62) 11.42 (2.69) 0.107 
Male gender (%)  21 (47.7%) 30 (65.2%) 0.094 
Gestation weeks median (IQR) 40 (38-41) 40 (38-40) 0.137 
Median birth weight in kg (IQR) 3.23 (2.72-3.52) 3.29 (2.81-3.57) 0.924 
Caucasian ethnicity (%) 41 (93.2%) 44 (95.7%) 0.609 
Recruited from tertiary centre (%) 28 (63.6%) 30 (65.2%) 0.984 
Age at diagnosis in years median (IQR) 1 (1 – 2) 2 (1 – 2) 0.514 
History of severity    
Median exacerbations in last year (IQR) 3.5 (2 – 8) 4.5 (2 – 7) 0.519 
Median oral corticosteroids courses last year 
(IQR) 
1 (0 – 3.5) 2 (0 – 3) 0.549 
Median number of hospital admissions ever 
(IQR) 
2 (0 – 5) 4 (1 – 8) 0.096 
Risk factors and exposures    
Maternal asthma (%) 18 (40.9%) 12 (26.1%) 0.136 
Father asthma (%)  15 (34.1%) 13 (28.3%) 0.550 
Household smoke exposure (%)  4 (9.1%) 6 (13.0%) 0.551 
Atopy (%) 30 (81.1%) 38 (88.4%) 0.363 
Baseline status and treatment    
Median PADQLQ (IQR) 130.5 (101.0-
145.0) 
125.0 (113.0-142.0) 0.936 
Asthma uncontrolled at screening (%)  12 (27.3%) 16 (34.8%) 0.709 
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Mean baseline FEV1 (SD) 87.2 (15.3) 91.1 (13.2) 0.193 
Mean FEV1 reversibility (SD) 6.39% (6.24) 6.96% (6.67) 0.677 
Median initial beclomethasone equivalent (IQR) 750 (400-1000) 800 (400-1000) 0.629 
Prescribed serevent/eformetol (%)  32 (72.7%) 36 (78.3%) 0.541 
Prescribed montelukast (%) 22 (50.0%) 24 (52.2%) 0.837 
Prescribed theophylline (%) 4 (9.1%) 2 (4.4%) 0.367 
Prescribed omalizumab (%) 0 (0%) 0 (0%)  
 
For continuous outcomes, means were compared by t-tests unless the data were skewed when 
non-parametric tests were used. Chi-squared tests were used to compare categorical outcomes. 
PADQLQ: Paediatric quality of life questionnaire score. IQR: interquartile range. 
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Table 4 Comparison of inhaled steroid therapy and annual exacerbation frequency in the FENO and standard therapy groups. 










Median total corticosteroid 
dose (IQR) 






FENO group 750 (400 to 1000) 800 (400 to 1000) 0 (−200 to 300) 264,800 (164,400 to 350,000) 3 (1-5) 84.1 
Standard 
management 
800 (400 to 1000) 500 (400 to 1000) 0 (−300 to 0) 249,600 (140,000 to 365,300) 2 (1-4) 82.6 
P-value  0.629 0.543 0.297 0.555 0.290 0.850 
 
Table includes data from all 90 randomised subjects. All doses are beclomethasone equivalents in micrograms. Median change in corticosteroid 
dose is the median of the differences between the doses at the initial and final visits. The total corticosteroid dose is the total dose received 
during 12 months follow-up assuming the dose reported at each visit accurately represents that taken for the preceding 2 months and 
extrapolating where necessary from the final dose in cases of incomplete follow-up. Exacerbation data was also extrapolated where a participant 
did not provide 12 months of data. P-values represent a two sample Mann-Whitney rank-sum test of the between groups difference of exacerbation 
frequency and chi-squared test for percentage in each group experiencing exacerbation. 
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